Marisa Wexler, MS, senior science writer —

The European Commission is expected to propose a new governing framework for health data next month, called the European Health Data Space (EHDS), with the aim of connecting national health systems to facilitate secure and efficient transfer of data across systems in different European nations. The move is expected to…

Treatment with oral valbenazine, a dopamine-modulating medicine, significantly eased the jerky, involuntary movements of chorea after as little as two weeks for Huntington’s disease patients in a completed Phase 3 clinical trial. More study participants given valbenazine also reported an improvement in their overall health status than did those randomized to…

Mutations in the HTT gene, which cause Huntington’s disease, lead to abnormalities in development as early as two weeks after conception, a new study indicates. The study, “Huntingtin CAG expansion impairs germ layer patterning in synthetic human 2D gastruloids through polarity defects,” was published in Development.

Sage Therapeutics is recruiting participants for a clinical trial to test the effects of its experimental therapy SAGE-718 on cognitive symptoms in people with Huntington’s disease. The Phase 2 study, called DIMENSION (NCT05107128), is seeking participants in select regions of the U.S. with additional sites in the…

People with Huntington’s disease who have a greater sense of purpose and meaning are more likely to find contentment in life and have better health-related quality of life, regardless of the severity of most of their symptoms. That’s according to the study “Meaning and purpose in…

Certain people with Huntington’s disease — specifically, younger adults with milder disease — may have benefited from treatment with tominersen in the Phase 3 GENERATION HD1 clinical trial, according to a new analysis of study data. Based on the results, its developer Roche is planning to launch a Phase 2…

People with Huntington’s disease are more likely to take Austedo (deutetrabenazine) as directed, compared with the similar medication Xenazine (tetrabenazine), according to a new study. The study also found lower discontinuation rates with Austedo, which may suggest that, between these two treatments for chorea, Austedo tends to…

The experimental oral medication branaplam (LMI070) has been granted fast track designation by the U.S. Food and Drug Administration (FDA) as a potential treatment for Huntington’s disease, according to an announcement from the therapy’s developer, Novartis. This designation is designed to speed the development and review of…

AMT-130, an investigational gene therapy for the treatment of Huntington’s disease, was overall well-tolerated up to a year after treatment in the first patients to receive the therapy in a clinical trial. The new data, announced by AMT-130’s developer uniQure, cover the first four participants in a Phase…

Treatment with valbenazine significantly lessened chorea — a motor symptom characterized by jerky, unpredictable, and involuntary movements — in people with Huntington’s disease in the Phase 3 clinical trial KINECT-HD, according to an announcement from the therapy’s developer, Neurocrine Biosciences. Neurocrine now is planning to submit an…